Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability

benzinga.com/markets/large-cap/25/09/47725519/sanofi-brivekimig-early-data-signals-strong-efficacy-and-good-tolerability

Sanofi SA (NASDAQ:SNY) shared new data from the HS-OBTAIN phase 2a study, which shows that treatment with brivekimig led to clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50) in patients naïve to biologics with…

This story appeared on benzinga.com, 2025-09-17 19:34:23.
The Entire Business World on a Single Page. Free to Use →